| Rank |
Status |
Study |
| 1 |
Unknown †
|
Eastbourne Syncope Assessment Study II
| Condition: |
Syncope |
| Interventions: |
Device: Sleuth Implantable Loop Recorder; Other: Other |
| Outcome Measures: |
Primary Outcome 1. Time to ECG (objective) diagnosis of Syncope; 1. Time to ECG directed therapy. 2. Time to introduction of empiric therapy. 3. Time to first post induction Syncope. 4. Cost effectiveness analysis. |
|
| 2 |
Recruiting
|
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
| Condition: |
Vasovagal Syncope |
| Interventions: |
Drug: midodrine hydrochloride; Drug: matching placebo |
| Outcome Measures: |
The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.; A secondary outcome will be the time between the first and second Syncope recurrences.; A secondary outcome will be the frequency of syncopal spells.; A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale(19)).; A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL. |
|
| 3 |
Not yet recruiting
|
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
| Condition: |
Vasovagal Syncope |
| Interventions: |
Drug: Metoprolol; Drug: Matching Placebo |
| Outcome Measures: |
The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.; A secondary outcome will be the time between the first and second Syncope recurrences.; A secondary outcome will be the frequency of syncopal spells.; A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale); A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL. |
|
| 4 |
Recruiting
|
Cardioneuroablation for Neurocardiogenic Syncope
| Conditions: |
Neurocardiogenic Syncope; Vasovagal Syncope |
| Interventions: |
Procedure: Cardioneuroablation; Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter |
| Outcome Measures: |
Recurrence of Syncope; Incidence of Serious Adverse Events |
|
| 5 |
Recruiting
|
Guideline-based Pacing Therapy for Reflex Syncope
| Condition: |
Syncope |
| Intervention: |
|
| Outcome Measures: |
Syncope recurrence after PM implantation; Syncope burden after PM implantation |
|
| 6 |
Recruiting
|
Stop Vasodepressor Drugs in Reflex Syncope
| Condition: |
Hypotensive Syncope |
| Interventions: |
Drug: Vasoactive drug therapies; Other: Stop/reduce vasoactive drugs |
| Outcome Measures: |
Recurrence of Syncope or preSyncope and adverse events; Syncope; PreSyncope |
|
| 7 |
Recruiting
|
Influence of Yoga in Patients With Neurocardiogenic Syncope
| Condition: |
Syncope, Vasovagal |
| Intervention: |
Other: Yoga |
| Outcome Measures: |
Change in frequency of recurrent syncopal spells in patients with Neurocardiogenic Syncope (NCS); Change in Heart Health |
|
| 8 |
Recruiting
|
Prevalence of Pulmonary Embolism in Patients With Syncope
| Conditions: |
Syncope; Pulmonary Embolism |
| Intervention: |
Other: Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer |
| Outcome Measures: |
To assess the prevalence of PE in a large series of consecutive patients presenting with the first episode of Syncope; To assess the prevalence of pulmonary embolism in patients with apparently unexplained Syncope |
|
| 9 |
Recruiting
|
Syncope: Pacing or Recording in the Later Years
| Conditions: |
Syncope; Heart Block; Conduction Disorder of the Heart |
| Interventions: |
Procedure: pacemaker; Procedure: implantable loop recorder |
| Outcome Measures: |
The primary outcome measure will be a composite of Major Adverse Study-Related Events (MASRE) in a 2-year observation period.; Secondary outcome measures will include total number of syncopal spells.; Secondary outcome measures will include the likelihood of a first recurrence of Syncope.; Secondary outcome measures will include the physical trauma due to Syncope.; Secondary outcome measures will include quality of life of the participants. |
|
| 10 |
Not yet recruiting
|
Syncope Prediction Study
| Condition: |
Vasovagal Syncope |
| Intervention: |
|
| Outcome Measure: |
Number of participants with Syncope recurrence predicted by VVS prediction algorithm |
|
| 11 |
Recruiting
|
Improving Syncope Risk Stratification in Older Adults
| Condition: |
Syncope |
| Intervention: |
|
| Outcome Measure: |
Combined death and serious cardiac events |
|
| 12 |
Recruiting
|
BAsel Syncope EvaLuation (BASEL IX) Study
| Condition: |
Syncope |
| Intervention: |
|
| Outcome Measure: |
diagnostic and prognostic value of various novel and established biomarkers, clinical assessment and detailed patient history |
|
| 13 |
Unknown †
|
Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions.
| Conditions: |
Cardiac Arrhythmia; Cardiogenic Syncope |
| Interventions: |
Device: repeated 24 hours ECG Holter monitoring; Device: Telemetric ECG monitoring |
| Outcome Measures: |
Recording of symptomatic or life threatening arrhythmia event; Occurrence of silent (asymptomatic) arrhythmia event; 1. Verification of patient self assessment based on the Quality of Life questionnaire and EHRA scale against evidence of cardiac arrhythmia occurrence |
|
| 14 |
Recruiting
|
Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope
| Condition: |
Neuromediated Cardioinhibitory Syncope |
| Intervention: |
Procedure: transcatheter ablation of ganglionated plexi in right atrium |
| Outcome Measure: |
neuromediated cardioinhibitory Syncope recurrence |
|
| 15 |
Recruiting
|
Mechanisms of Vasovagal Syncope
| Conditions: |
Vasovagal Syncope; Postural Tachycardia Syndrome |
| Interventions: |
Drug: Phenylephrine; Drug: L-Ng-monomethyl Arginine (L-NMMA) |
| Outcome Measures: |
Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP); Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion |
|
| 16 |
Recruiting
|
Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope
| Condition: |
Syncope |
| Intervention: |
Other: Point-of-Care Ultrasound |
| Outcome Measures: |
Time to Final Emergency Department Disposition; Time to therapeutic intervention; Time to clinical procedure; Number and Type of other imaging studies; Information Content provided by Point-of-Care Ultrasound; Number and type of laboratory studies; Number of and time to consultant services |
|
| 17 |
Unknown †
|
Adenosine Testing to DEtermine the Need for Pacing Therapy
| Condition: |
Syncope |
| Interventions: |
Device: Pacemaker implantation (Medtronic); Device: Implantable Loop Recorder (Medtronic) |
| Outcome Measures: |
Syncope Burden; Time to first Syncope; Number of patients with recurrent Syncope; Quality of life; Health economic analysis; ECG diagnosis on ILR following syncopal episode in adenosine negative group |
|
| 18 |
Recruiting
|
Evaluation of the Efficiency of Hydration by Isotonic Solution in the Prevent of the Fainting Whole Blood Donors
| Conditions: |
Fainting; PreSyncope; Syncopal Episode |
| Interventions: |
Other: tensing exercises; Other: No tensing exercises |
| Outcome Measures: |
Accumulated incidence of presyncopal and syncopal reactions during blood donation, while still at the blood donation whole and within 48 hours of the blood donation, that required the donor to be placed in a 'Trendelenburg' position; daily activities; presyncopal and syncopal reactions of all donors; presyncopal and syncopal reactions in the population of young donors (in schools); presyncopal or syncopal reactions influence on subsequent blood donation; Recurrence of presyncopal or syncopal reactions; Explanatory variables of presyncopal and syncopal reactions; subgroup analysis on collection unit characteristics; medium term impact of the donation; Restless legs syndrome |
|
| 19 |
Unknown †
|
Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders
| Condition: |
Vagal Syncope |
| Interventions: |
Biological: Blood sampling; Other: ECG-Holter 24 h tape and sino-carotid stimulation test |
| Outcome Measure: |
|
|
| 20 |
Recruiting
|
Essential Hypotension and Adaptability Registry
| Conditions: |
Blood Pressure; Depression; Panic Attack; Fibromyalgia; POTS; Inappropriate Sinus Tachycardia; Coronary Heart Disease; Acute Coronary Syndrome (ACS); Acute Myocardial Infarction (AMI); Cerebrovascular Disease (CVD); Transient Ischemic Attack (TIA); Atrial Fibrillation; Diabetes Mellitus; Cancer; Systolic Heart Failure; Diastolic Heart Failure; Chronic Fatigue Syndrome; Syncope; Vasovagal Syncope |
| Intervention: |
|
| Outcome Measures: |
Relationship between Blood pressure group and comorbidities; Relationship between adaptability group and comorbidities; Relationship between blood pressure group, adaptability group and comorbidities; Relationship between blood pressure group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM); Relationship between blood pressure group, adaptability group, habits anthropometric, metabolic, endocrine, electrocardiographic, Holter, ambulatory arterial blood pressure monitoring.; For metabolic disorders what it matters the most: the anthropometric variables vs blood pressure group vs adaptability group; Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM) |
|
